PLK2 and glioblastoma: Interestingly, consistent with our previous findings, GBM patients with high ITGA5, COL6A1, SERPINA5, NRP1, PLK2, ANXA1, and PDPN expression had worse survival outcomes, whereas GBM patients with low MAPK1 and HEY1 showed worse survival outcomes (Figure S8).